37results about How to "Reduce expression" patented technology

This invention discloses the application of Uncaria rhynchophylla neutral polysaccharide URP-W in the preparation of anti-glioma drugs, belonging to the field of anti-tumor technology of medicinal plant polysaccharides. The invention obtains a crude polysaccharide extract from Uncaria rhynchophylla through hot water extraction and ethanol precipitation, followed by purification using a DEAE cellulose column and G200 dextran gel to obtain Uncaria rhynchophylla neutral polysaccharide URP-W. The monosaccharide composition of URP-W includes arabinose, rhamnose, galactose, glucose, xylose, mannose, galacturonic acid, and mannuronic acid in a molar ratio of 17.99:6.32:21.71:27.17:2.56:7.57:16.20:0.49. Experiments have shown that URP-W can inhibit the proliferation of gliomas and induce apoptosis, exhibiting significant anti-tumor activity against glioma cells, providing a new drug raw material and treatment method for the clinical treatment of gliomas.

The invention provides a rhizoma bletillae composition as well as a preparation method and application thereof, and relates to the technical field of traditional Chinese medicine preparations. The core effective component of rhizoma bletillae is rhizoma bletillae polysaccharide, the rhizoma bletillae polysaccharide has the effects of film forming, hemostasis, targeted wound repair promotion and infection prevention, tea polyphenol and rhizoma bletillae are compounded for use, the tea polyphenol and rhizoma bletillae synergistically resist inflammation, the expression quantity of proinflammatory factors IL-1beta, TNF-alpha and IL-6 is reduced by inhibiting NF-kappa B and MAPK signal channels, the inflammatory cascade reaction is remarkably blocked, and the anti-inflammatory effect is achieved. Red, swollen and pain caused by inflammation are effectively relieved, and wound healing is accelerated. In addition, the rhizoma bletillae and the tea polyphenol can also generate a synergistic antibacterial effect, and compared with a single rhizoma bletillae component, the probability of wound infection is further reduced; the compounding use of the rhizoma bletillae and the tea polyphenol also inhibits the excessive deposition of collagen, reduces the scar area, reduces the scar hyperplasia degree, and makes up the blank of only promoting healing and not preventing scars for burns and scalds in the prior art.

The TaSL1 protein or biological material provided by this invention has the function of increasing the number of grains per ear and the length of the ear in wheat. After reducing the expression of TaSL1 protein in wheat, the transgenic wheat obtained has a significantly increased number of grains per ear, ear length, and awn length compared with the control. The TaSL1 protein or biological material provides a new genetic resource for breeding wheat varieties with high grain count and long ears, which is of great significance for improving wheat yield.

The application provides a dsHpAGO1 for preventing and controlling holotrichia larvae and application thereof, and belongs to the field of biotechnology and agricultural application. The dsHpAGO1 in the application is synthesized by an HpAGO1 gene with a nucleotide sequence as shown in SEQ ID NO. 1 and dsRNA primers with nucleotide sequences as shown in SEQ ID NO. 3 to SEQ ID NO. 4. After the holotrichia larvae are injected with the dsHpAGO1 in the application, the expression amount of the HpAGO1 gene is significantly reduced compared with a control group, the interference efficiency is 95.53%, the holotrichia larvae grow and develop abnormally, and a large number of holotrichia larvae die, the mortality rate is 91.7%, and the silencing efficiency of the HpVAA gene is reduced by 42.6%. Therefore, the dsHpAGO1 in the application has great significance in the prevention and control of holotrichia larvae.

This invention discloses the application of *Lactobacillus animalis* ATCC35046 in the preparation of anti-aging drugs. The *Lactobacillus animalis* ATCC35046 involved in this invention is colonized in dental plaque of primates and in the intestines of dogs and mice. It can significantly reduce the expression of P16 or P21 in brain, bone, muscle, and skin tissues, significantly downregulate the level of aging-related secretory phenotypes in serum, and improve spatial memory, motor function, and muscle function. This provides a theoretical reference and guidance for the development of multi-target, multifunctional anti-aging probiotic preparations.

The invention discloses a method for regulating polarization of microglial cells through a Chuk / NF-kB pathway in electroshock treatment, and relates to the field of biomedicine. According to the method, by simulating an anti-inflammatory mechanism of electroshock treatment, expression of a Chuk gene in the microglial cells is knocked down by adopting specific siRNA, so that activation of an NF-kB signal channel is inhibited, conversion of the microglial cells from an M1 type pro-inflammatory polarization state to an M2 type anti-inflammatory polarization state is regulated, and the method specifically comprises the following steps: culturing and grouping the microglial cells; carrying out siRNA transfection; lPS-induced inflammation; detecting indexes; according to the invention, after an electroshock treatment mechanism is simulated and the Chuk gene is knocked down, LPS-induced NF-kB pathway activation is significantly inhibited, the expression of proinflammatory factors is reduced, and the level of anti-inflammatory factors is improved at the same time.

This invention relates to the field of biomedical technology, and in particular to the application of triptolide or its pharmaceutically acceptable salts in the preparation of medicaments for treating ketoacidosis or its symptoms. This invention provides the application of triptolide or its pharmaceutically acceptable salts in the preparation of medicaments for treating ketoacidosis or its symptoms. Results from specific embodiments of this invention show that triptolide can significantly reduce serum β-hydroxybutyrate levels in mice induced by starvation; triptolide can significantly reduce HMGCS2 expression in mouse livers; dapagliflozin significantly promotes β-hydroxybutyrate levels, while triptolide significantly reduces serum β-hydroxybutyrate levels in mice treated with dapagliflozin. Therefore, triptolide can be used to treat or improve ketoacidosis or its symptoms. This invention provides a new technical solution for the treatment and improvement of ketoacidosis or its symptoms.

The invention discloses siRNA (small interfering Ribonucleic Acid) targeting BACH1 and application of the siRNA in preparation of chronic pain treatment medicines, belongs to the field of biological medicines, and discloses a compound, a composition and a method for regulating BACH1 gene expression, regulating response of activity and regulating characters, diseases or conditions of a BACH1 gene expression pathway. A behavioral result shows that the group of siRNAs can significantly inhibit mechanical hyperalgesia generated by peripheral nerve injury induction; the siRNA is injected into the trigeminal ganglion of a neuropathic pain model mouse, molecular biology experiments show that the siRNA can remarkably reduce expression of BACH1 in the trigeminal ganglion of the mouse in vivo, a new target and a new method are provided for research and development of chronic pain treatment drugs, non-chemical modification and chemical modification nucleic acid molecules of the targeted BACH1 gene are provided, and the application prospect is wide. The traditional Chinese medicine composition has a good medicine effect on chronic pain, lays a foundation for medicine preparation for treating chronic pain, and has great application and popularization value.

The application discloses an anti-MAK16-IgG1 monoclonal subtype antibody and a preparation method and application thereof, and belongs to the technical field of immunological disease drugs. The application successfully prepares a high-concentration high-purity monoclonal antibody against MAK16 protein, which is a monoclonal IgG1 subtype antibody, namely anti-MAK16-IgG1 monoclonal subtype antibody; the titer is 160000; compared with RAW264.7 cells in a group stimulated and induced by IgG1+LPS, the expression amounts of IL-6 and IL-10 in RAW264.7 cells after 24h and 48h of stimulation and induction by the anti-MAK16-IgG1 monoclonal subtype antibody prepared by the application and LPS are significantly reduced, and the difference is more obvious with the prolongation of time; the effective dose of the anti-MAK16-IgG1 monoclonal subtype antibody is not less than 50 mu g / mL.

The application discloses application of Danshensu in preparation of a product for preventing and treating peritoneal dialysis related peritoneal fibrosis, and belongs to the field of medicines. The application proves that direct use of Danshensu can improve peritoneal dysfunction induced by peritoneal dialysis, reduce peritoneal thickening and collagen deposition, inhibit epithelial-mesenchymal transition of peritoneal mesothelial cells, reduce expression of alpha-SMA and VEGFA, increase expression of E-cadherin, and resist peritoneal fibrosis through inhibition of a STAT3 signal pathway.

The invention discloses application of an extracellular matrix in preparation of an anti-vascular aging product, and belongs to the field of biological medicine. The acellular extracellular matrix provided by the invention is prepared by taking umbilical artery vascular smooth muscle cells as a material and carrying out water swelling and 0.5% Triton X-100 treatment on the umbilical artery vascular smooth muscle cells. The invention also provides application of the acellular matrix in preparation of drugs for inhibiting blood vessel and cell senescence. Experimental results show that after aortic vascular smooth muscle cells overexpressing Pelamin A are inoculated to the acellular matrix and cultured, the aortic vascular smooth muscle cells are distributed in a concentrated manner, the number of the aortic vascular smooth muscle cells is increased, the form of the aortic vascular smooth muscle cells is remarkably improved, the expression of X-GAL in the cells is reduced, and the expression quantity of Ki67 is increased; therefore, the acellular extracellular matrix provided by the invention can be used for effectively regulating aortic vascular smooth muscle cell senescence induced by Pelamin A accumulation. The invention provides a new biological material for inhibiting vascular aging and cell aging.

The application belongs to the field of plant genetic engineering, and specifically discloses a Rosa chinensis RchChr3g0469531 (PIP2;1) gene and application thereof in regulation of thorn trait. The application finds that the RchChr3g0469531 (PIP2;1) located in the QTL1 interval is differentiated in the Rosa chinensis population with or without thorn and is specifically expressed in thorn tissue. Therefore, a modern Rosa chinensis Samantha (thorny Rosa chinensis variety R. 'Samantha') is taken as a material, a silencing vector is constructed through virus-mediated gene silencing (VIGS) to transform the Rosa chinensis, and the expression of the RcPIP2;1 gene in the Rosa chinensis is detected. The results show that the expression amount of the PIP2;1 is significantly reduced to about 25% after gene silencing, and combined with the thorn number phenotype, it is further determined that the RcPIP2;1 gene is a positive regulation factor of the thorn occurrence of the Rosa chinensis, and has important application value in cultivating new germplasm of few-thorn or thornless Rosa chinensis and improving field management of the Rosa chinensis.

The invention discloses an application of a neuron-derived neurotrophic factor NDNF in promotion of regenerative repair and functional reconstruction of an injured heart, particularly relates to an application of the NDNF in a medicine for treating or improving the injured heart, a recombinant vector and a medicine, and belongs to the technical field of biological medicines. The invention provides application of NDNF in promotion of regenerative repair and functional reconstruction of damaged heart. The invention proves that the medicine prepared from the NDNF can be used for treating or improving the insufficiency and inflammation of the damaged heart, and particularly has a good treatment effect on the damaged heart caused by myocardial infarction, and the treatment effect specifically comprises the effect of reducing myocardial cell apoptosis and inflammation after myocardial infarction and the effect of inhibiting myocardial cell pathological hypertrophy after myocardial infarction due to overexpression of the NDNF. In addition, overexpression of the NDNF can also promote proliferation of myocardial cells after myocardial infarction.

The application discloses a kind of detection piRNA marker material, including one or more of the following applications: A1) in the application in the preparation of diagnostic blood vessel senile product;A2) in the application in the preparation of screening blood vessel senile product;A3) in the application in the preparation of evaluating blood vessel senile risk product;A4) in the application in the preparation of blood vessel senile prognosis evaluation product;A5) in the application in the preparation of distinguishing blood vessel senile and other diseases product;PiRNA marker is hsa_piR_017724, nucleotide sequence is as shown in SEQ ID No.1.The hsa_piR_017724 marker provided by the application is significantly increased in the expression amount in the plasma of blood vessel senile patient compared with healthy control, indicating that hsa_piR_017724 is a potential blood vessel senile biomarker.The ROC curve of the efficiency in diagnosing blood vessel senile patient shows that hsa_piR_017724 has good diagnostic efficiency.

Methods that may be used for the manufacture of the chemical compound (R)-Reticuline and synthesis precursors thereof. Compositions useful for the synthesis (R)-Reticuline and synthesis precursors are also provided.

The invention relates to an anti-dengue virus medicine containing a ferroptosis inhibitor and application of the anti-dengue virus medicine, in particular to medical application of the ferroptosis inhibitor in resisting dengue virus infection. In-vitro experiments prove that DENV infection can activate a host cell ferroptosis pathway; after 1-3 [mu] M of Ferrostatin-1 or Liproxstatin-1 is adopted for intervention, the activation of the pathway can be effectively inhibited, and the virus RNA replication and protein expression level can be remarkably reduced. According to the technical scheme, the existing activity of the known ferroptosis inhibitor is utilized, new indications for resisting DENV infection of the ferroptosis inhibitor are developed, a candidate drug strategy of a targeted ferroptosis pathway is provided for dengue treatment, the technical problem that the action target of an existing antiviral drug is limited is solved, and the obvious clinical application and development value is achieved.

This invention provides a cytochrome P450 gene HvCYP94C1 and its application in improving the resistance of highland barley to powdery mildew, belonging to the field of agricultural biotechnology. The cytochrome P450 gene HvCYP94C1 of this invention can hydroxylate JA and JA-Ile to 12-OH-JA-Ile and 12-COOH-JA-Ile, respectively. Silencing this gene in powdery mildew-sensitive materials can significantly increase the jasmonic acid content, thereby improving the disease resistance of the materials, showing excellent application prospects.

The application discloses Siberian apricot PsMADS19 genes, coding proteins, primer groups, recombination carriers and application thereof in regulating flowering time of plants. A coding sequence of the PsMADS19 gene is shown as SEQ ID NO. 1, and an amino acid sequence of a coding protein of the PsMADS19 gene is shown as SEQ ID NO. 2. The expression amount of the PsMADS19 gene in a transgenic plant is significantly increased, the bolting and flowering time is delayed, and the flowering period can be effectively delayed. The application further discloses specific primers of the PsMADS19 gene and primers for fluorescence quantitative PCR. The application further provides a main gene and a molecular breeding method for late flowering and frost resistance breeding of Siberian apricot and other plants, and has important theoretical value and production application prospect.

The invention discloses miR-184 and application of the miR-184 in regulating and controlling the reproduction of female diaphorina citri. The nucleotide sequence of the micromolecule miR-184 provided by the invention is shown as SEQ ID NO.4, and the micromolecule miR-184 is highly expressed in the ovary of the female diaphorina citri. By feeding the miR-184 agonist, the egg laying amount of the diaphorina citri is obviously reduced, the development of the ovary is inhibited, the titer of the Candidatus Liberibacter asiaticum in the ovary is obviously reduced, and the miR-184 agonist has a good application prospect in the aspects of regulating and controlling the reproduction of female diaphorina citri, preventing and treating the female diaphorina citri, preventing the Candidatus Liberibacter asiaticum and the like.

This invention provides a tuna multi-target antihypertensive peptide and its applications. The amino acid sequence of the peptide is one or more of FAPF, VSFP, FQPSF, and FFLP, and it is a bioactive peptide possessing ACE2 upregulation, ET-1 downregulation, and ACE inhibitory activities. The tuna multi-target antihypertensive peptide provided by this invention is prepared from yellowfin tuna scraps. This bioactive peptide has excellent biocompatibility, small molecular weight, and high activity, making it easy to isolate, purify, and synthesize artificially. This invention utilizes Ang-II-induced HUVEC cells to isolate and purify a novel bioactive peptide with ACE2 upregulation, ET-1 downregulation, and ACE inhibition from tuna hydrolysate. This overcomes the problem of blood pressure reversal after long-term use of single-target ACE inhibitory peptides and can synergistically exert a better antihypertensive effect with ACE inhibitory peptides.

An LPA RNA interference (RNAi) agent, comprising nucleotides targeting a nucleic acid molecule encoding LPA(apo(a)), the oligonucleotide comprising at least 12 consecutive nucleotides in any one of the nucleotide sequences SEQ ID NO:2 to SEQ ID NO:92. A pharmaceutical composition comprising one or more RNA interference agents, in vivo delivery of the RNA interference agent to liver cells providing inhibition of LPA gene expression, and the use of the nucleic acidbased therapeutic agent to lower lipoprotein(a) (Lp(a)) and treat or prevent cardiovascular-related diseases.

Provided are anti-IL-4R [alpha] antibodies or antigen binding fragments thereof, anti-TSLP antibodies or antigen binding fragments thereof, antigen binding protein constructs (e.g., multispecific or bispecific antibodies capable of specifically binding IL-4R [alpha] and TSLP). Polynucleotides encoding the antibody or antigen binding protein constructs, as well as expression vectors and host cells comprising the same, are provided. Also provided are immunoconjugates, pharmaceutical compositions, and medicaments, as well as their use in the treatment of immune disorders, such as type II or hybrid allergic diseases.

The invention relates to the technical field of crossing of a stem cell engineering technology, a nano-drug delivery system and a gene therapy technology, in particular to a PEI-LNPmiR-21 delivery system, a preparation method and application thereof and an engineered long-acting stem cell preparation. According to the delivery system, a lipid nanoparticle core is prepared by adopting a microfluidic technology, and low-molecular-weight PEI is covalently grafted on the surface of a lipid layer by utilizing carbodiimide chemistry, so that a nano compound with a core-shell structure is formed. The compound can efficiently deliver miR-21 into stem cells, and by regulating and controlling a PTEN / PI3K / Akt signal channel, the expression of a cell aging marker is remarkably inhibited, the proliferation capacity of the stem cells is enhanced, and the stemness characteristic of the stem cells is maintained.

The present invention relates to an o / w emulsion comprising an oil phase, an aqueous phase and particles dispersed in the aqueous phase, wherein the particles are lipid nanoparticles (LNP) comprising a nucleic acid component, the particles being capable of stabilizing the oil-water interface. The invention also discloses a pharmaceutical composition, such as a vaccine, comprising the o / w emulsion.

This invention provides a double-stranded oligonucleotide targeting TSLP mRNA and its applications, relating to the field of biotechnology. The sense strand of this double-stranded oligonucleotide contains a sequence that differs from the sequences shown in SEQ ID NO. 1, 3, 5, 7, etc. by no more than 8 nucleotides; the antisense strand contains a sequence that differs from the sequences shown in SEQ ID NO. 2, 4, 6, 8, etc.; and the sense and antisense strands are at least partially anticomplementary to form a double-stranded region. This double-stranded oligonucleotide can inhibit TSLP mRNA, reduce TSLP protein expression in subjects, and can be used to prepare drugs for the treatment and / or prevention of TSLP-related diseases.

This invention discloses the application of the rose gene RhMYB1 in regulating axillary bud germination in roses. Relating to the field of molecular biology, this invention provides the application of products that inhibit the expression of the RhMYB1 gene or its transcribed and translated protein in regulating axillary bud germination in roses. The nucleotide sequence of the RhMYB1 gene is shown in SEQ ID NO.1. Based on the expression results of the RhMYB1 gene at different sites in rose buds, this invention found that its expression level is higher in upper buds (i.e., active buds). Transient silencing of the RhMYB1 gene in axillary buds showed that silencing the RhMYB1 gene significantly inhibited the germination and growth of axillary buds, while overexpression of RhMYB1 promoted the growth of axillary buds.

The invention provides an enterokinase light chain recombinant protein and application and a method for efficient soluble expression of a recombinant enterokinase light chain, the enterokinase light chain recombinant protein is composed of more than two fusion proteins AgSg or mutants thereof and an enterokinase light chain or mutants thereof, the amino acid sequence of the fusion proteins AgSg is shown as SEQ ID NO.3, and the amino acid sequence of the fusion proteins AgSg is shown as SEQ ID NO.3. The amino acid sequence of the enterokinase light chain is as shown in SEQ ID NO. 1; according to the enterokinase light chain recombinant protein, a specific amount of fusion protein AgSg derived from the N end of spider silk sericin is fused with an enterokinase light chain or a mutant thereof in a series connection manner, so that the expression quantity of the enterokinase light chain or / and the mutant can be remarkably improved, and the enterokinase light chain or / and the mutant can be expressed in a soluble form; the defects that a traditional escherichia coli system is low in expression quantity and expression and purification are difficult in an inclusion body form are overcome, and the method can be applied to production of high-efficiency soluble enterokinase light chains.

This invention belongs to the field of biomedical technology and relates to a polypeptide targeting cGAS and its applications. The polypeptide comprises an active peptide and a membrane-penetrating peptide, the membrane-penetrating peptide being fused to the N-terminus of the active peptide. The amino acid sequence of the active peptide is identical to amino acid regions 45-63 of human IκB kinase-binding protein (IKIP) or 43-60 of mouse IKIP. The polypeptide provided by this invention can enter cells, specifically bind to cGAS, inhibit cGAS aggregation and phase separation, thereby inhibiting cGAS enzyme activity, reducing type I interferon expression, maintaining antiviral immune homeostasis, and providing a new candidate strategy for the clinical treatment of viral infections and autoimmune diseases.

This invention discloses a medical material for the prevention and treatment of oral ulcers, its preparation method, and its application. The medical material of this invention comprises a two-dimensional sheet-like nanomaterial composed of an organic matrix and metallic elements. The two-dimensional sheet-like nanomaterial of this invention possesses advantages such as high crystallinity, favorable material transport, high healing rate, reduced recurrence risk, excellent biocompatibility, mild preparation process, scalability, ease of use, and low cost, and has broad application prospects in the field of oral ulcer prevention and treatment.